Skip to main content
. 2020 Mar;8(5):230. doi: 10.21037/atm.2020.01.32

Figure S7.

Figure S7

Progression-free survival analysis in the MSK cohort stratified by gene mutation status. (A) Progression-free survival analysis on immune checkpoint inhibitor for patients with CTNNB1 mutation versus CTNNB1 wild-type tumors. (B) The same analysis as (A), but patients with MLL mutations were compared MLL wild-type tumors. HR, hazard ratio; CI, confidence interval.